Bull
$1.53
シナリオ価格
$4.320
+0.124 (+2.86%)終値時点
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
H.C. Wainwright
$10
2026-04-09
H.C. Wainwright
2026-04-09
目標株価
$10
H.C. Wainwright
$14
2025-05-16
H.C. Wainwright
2025-05-16
目標株価
$14
Piper Sandler
—
2025-05-15
Piper Sandler
2025-05-15
目標株価
—
Jefferies
$2
2025-04-04
Jefferies
2025-04-04
目標株価
$2
HC Wainwright & Co.
$19
2025-03-28
HC Wainwright & Co.
2025-03-28
目標株価
$19
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Focal One® HIFU Treatment Shows Significant Improvement in Endometriosis Symptoms

EDAP Rebrands to FocalTherics, Emphasizing Robotic Therapy Focus

EDAP TMS to Present at Jefferies 2026 Global Healthcare Conference

Telix Partners with Leaders in Ablative Technologies for Prostate Cancer

Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
2 analysts cover EDAP: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 8.25.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。